Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guérin by 김세종 et al.
Clin Exp Immunol 1995; 100:26-31
Induction of tumour necrosis factor-alpha (TNF-a) mRNA in bladders
and spleens of mice after intravesical administration of bacillus
Calmette-Guerin
J. S. SHIN, J. H. PARK, J. D. KIM, J. M. LEE* & S. J. KIM Department of Microbiology and *Urology, Yonsei
University College of Medicine, Seoul, Korea
(Acceptedfor publication 29 November 1994)
SUMMARY
Intravesical bacillus Calmette-Guerin (BCG) therapy is highly effective in the therapy of
carcinoma in situ of the bladder, but the mechanism of BCG immunotherapy is not clearly
understood. We studied the production ofTNF-a in spleens and bladders of mice after intravesical
BCG or BCG/interferon-gamma (IFN--y) instillation. Significant change of TNF-ca mRNA
expression of spleens and bladders of C3H/He mice was observed after intravesical BCG
instillation, although intravesical IFN--y therapy 3 days after BCG instillation to maintain the
activated state of monocyte/macrophage lineage cells did not show a significant change of TNF-a
mRNA, compared with that of BCG therapy alone. Maximal production of TNF-a mRNA in
spleens of mice was seen after the first or second intravesical BCG instillation, and production of
TNF-ac mRNA in bladders was also increased after intravesical BCG instillation. The increment of
TNF-a production by BCG stimulation in HL-60, a promyelocytic leukaemic cell line, and
peripheral blood mononuclear cells in vitro may support the in vivo effect of BCG therapy on the
bladder. These data show that local production of TNF-ac as well as systemic production by
intravesical BCG treatment may correlate with one of the mechanisms of BCG immunotherapy of
superficial bladder cancer.
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INTRODUCTION
Intravesical bacillus Calmette-Guerin (BCG) immunotherapy
is considered to be one of the effective treatments for superficial
bladder cancer and carcinoma in situ of the bladder [1-5].
Although the action mechanism of intravesical BCG immu-
notherapy is not clearly understood, an immune response to
BCG has been known to be associated with anti-tumour
activity. Congenital T lymphocyte-deficient mice transplanted
with bladder tumours fail to respond to intravesical BCG
treatment until T lymphocytes are given [6]; this result shows
that successful intravesical BCG immunotherapy depends on
an intact cellular immune function. Also, many clinical studies
of intravesical BCG instillation reveal that the development of
immunological responses to BCG is associated with anti-
tumour activity [7- 11].
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Intravesical BCG therapy induces the production of lym-
phokines such as IL-1, IL-2, interferon-gamma (IFN-y), and
TNF-a [12-14] in urine, and BCG-induced lymphokines may
be associated with anti-tumour activities [12-13]. The elevated
level of TNF-a in urine may play a major role in the cytotoxic
activity of BCG [13,151, but the origin of TNF-a in urine has
not yet been identified.
IFN-y is a peptide cytokine produced by antigen-specific T
cells during an immune response, and has been shown to have
several actions of relevance to tumour immunology. It fulfils a
number ofimmunomodulatory functions, notably activation of
macrophages and natural killer (NK) cells, and proliferation
and activation of T and B cells [16].
In the present study, we studied production of TNF-a
mRNA in spleens and bladders of mice after intravesical
BCG instillation to observe the local and systemic immuno-
logical effects of intravesical BCG treatment in inducing the
production of TNF-a. The changes of TNF-a mRNA level in
bladders and spleens of mice were also observed to determine
the applicability of IFN--y in addition to BCG.
TNF-a mRNA production in BCG immunotherapy
MATERIALS AND METHODS
Mice and BCG
Female C3H/He mice, 6-8 weeks old, were used, and Pasteur
strain BCG, 1 x 105 colony-forming units (CFU), was sus-
pended in normal saline and instilled into the bladder via a
Teflon catheter.
Human and mouse TNF-a cDNA
Human TNF-a cDNA clone was obtained from the American
Type Culture Collection (ATCC, Rockville, MD), and mouse
TNF-a cDNA clone was kindly given by Dr P. Vassalli
(Departement de Pathologie, Centre Medical Universitaire,
Geneva, Switzerland), which contains the 696 Taq-EcoRI
fragment of the mouse TNF gene [17]. The human -y-actin
probe was a generous gift from Dr S. Y. Yang (Memorial Sloan
Kettering Cancer Centre, New York, NY).
TNF-a mRNA expression in vitro
HL-60 (ATCC CCL 240), a promyelocytic leukaemic cell line,
and human peripheral blood mononuclear cells (PBMC) were
used to observe the effect ofBCG and IFN--y on TNF-a mRNA
induction in vitro. The HL-60 cells were cultured in RPMI 1640
medium (supplemented with 100 U/ml penicillin, 100 pg/ml
streptomycin, and 2mM L-glutamine) with 10% fetal bovine
serum (FBS; GIBco BRL, Grand Island, NY). The TNF-a
mRNA was induced by recombinant human (rh) IFN--y
(Genzyme Co., Cambridge, MA) 50 or 500 U/ml, BCG
1 x 105 CFU/ml with rhIFN--y 50 or 500U/ml, and 20pg/ml
lipopolysaccharide (LPS; Escherichia coli 055:B5; Sigma, St
Louis, MO), and cells were cultured for 4 h in humidified 5%
C02, 37°C incubator. Cytoplasmic total RNA was isolated by a
caesium chloride gradient centrifugation [18] after lysing the
cells by guanidine isothiocyanate solution [19].
PBMC were obtained from the heparinized (20 U/ml)
peripheral blood of two normal persons by Ficoll-Hypaque
(Pharmacia, Piscataway, NJ) density gradient centrifugation at
4°C. PBMC were washed with ice-cold RPMI 1640, and
cultured in RPMI 1640 with 10% human AB serum. TNF-a
mRNA was induced by BCG 20 pg/ml with rhIFN-7 50 or
500 U/ml, and LPS 20 pg/ml for 4 h [20]. Cytoplasmic total
RNA was isolated by the guanidine isothiocyanate-phenol
chloroform method [21]. TNF-a mRNA were detected by the
Northern blot hybridization method [22].
TNF-a mRNA in spleens and bladders ofmice
The mouse bladder tumour cell line, MBT-2, from which signal
of TNF-a mRNA could not be detected in our experiment
(data not shown), was maintained in RPMI 1640 (Hazleton,
Lenexa, KS) with 10% FBS. MBT-2 cells were washed with
RPMI 1640 and implanted into the bladders as described
previously [23]. Briefly, mice were placed under light general
anaesthesia with i.p. sodium pentobarbital (0-05 mg/g animal
weight), and bladders were catheterized with a cautery elec-
trode which was guided by a 24G teflon catheter under 10-fold
magnification power. The electrode was activated with a Bovie
unit for 4 s at the lowest coagulation setting, and 5 x 105 viable
MBT-2 cells were injected into the bladder. Intravesical BCG
treatments were started 24 h after tumour implantation, and
BCG 1 x 105 CFU was instilled weekly for 5 weeks. Recombi-
nant mouse IFN-,y (Genzyme) 3000U per injection was
instilled into the bladder 3 days after intravesical BCG treat-
ment. Spleens and bladders of mice were removed to observe
the expression of TNF-a mRNA after 1 week of final BCG
treatment. Total cellular RNA of spleens were isolated by a
caesium chloride gradient centrifugation, and those of bladders
by the guanidine isothiocyanate-phenol-chloroform method
[21] after homogenizing the tissue. Each test group consisted of
three or four mice, and the expressions of TNF-a mRNA of
spleens and bladders were detected by the slot blot hybridiza-
tion method [24,25]. Control mice were also catheterized with a
cautery electrode, and then MBT-2 cells were injected into the
bladders as in the experimental mice, and spleens and bladders
were removed after 1 week.
Northern blot and slot blot analysis
Northern blot analysis was performed to observe TNF-a
mRNA induction in HL-60 cells and PBMC. Briefly, isolated
total cellular RNA was denatured with 50% formamide/17-5%
formaldehyde/20 mm 3-[N-morpholino] propanesulphonic acid
(MOPS) at 65°C for 15 min, and electrophoresed on a formal-
dehyde denaturing gel (1% agarose, 5*4% formaldehyde), and
then transferred to a nylon membrane (Bios Co., New Haven,
CT). The transferred RNA was fixed on the nylon membrane
by an ultraviolet crosslinker (Hoeffer Scientific Instruments,
San Francisco, CA) and prehybridized at 42°C overnight. The
prehybridization solution contained 50% formamide/5 x SSC/
5 x Denhardt's solution (0 1% bovine serum albumin (BSA)/
0 1% polyvinylpyrrolidone/0 1% Ficoll)/l% SDS/250 Ig/ml
denatured herring sperm DNA/50mm sodium phosphate
buffer, pH7 0. Hybridization was performed at 42°C over-
night in the hybridization solution (50% formamide/5 x SSC/
1 x Denhardt's solution/0-1% SDS/10% dextran sulphate/
250 jig/ml denatured herring sperm DNA/50mm sodium phos-
phate buffer, pH 7 0).
Slot blot analysis was done to observe TNF-a mRNA
expression in spleens and bladders of mice. Briefly, a wet
nylon membrane with 20 x SSC was fixed on the slot blot kit
(Hoeffer) and prewashed with 10 x SSC. Heat-denatured RNA
in 50% formamide/7% formaldehyde/l x SSC was blotted to a
nylon membrane through the slots, each slot was washed with
10 x SSC, and the RNA was fixed on the membrane by an
ultraviolet crosslinker. The nylon membrane was prehybri-
dized, and then hybridized overnight. a-32P-labelled TNF-a
cDNA probes by a random primer labelling kit (Amersham
International, Aylesbury, UK) were used to detect signals
[26,27]. The specific activity of labelled DNA, which was
calculated by the formula of ((total ct/min incorporated)/(jig
DNA synthesized + ltg of input DNA)), was 2 x 109 ct/min
per ,ug. The hybridized nylon membrane was washed with
solution A (6 x SSC/02% SDS) at room temperature for
20 min, and with solution B (1 x SSC/1% SDS) at 42°C for
20 min, and with solution C (0- 1 x SSC/1% SDS) at 50°C for
60 min. The intensity of each band was expressed by the value
of optical density and compared with a laser scanning densit-
ometer (Pharmacia LKB, Uppsala, Sweden) at 633 nm of
absorbance after autoradiography.
RESULTS
TNF-a mRNA induction in HL-60 and PBMC
The human promyelocytic cell line, HL-60, produces barely
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Fig. 1. Northern blot analysis of TNF-a mRNA of HL-60 cells. Each
lane was loaded with 20lig/well of total cellular RNA. Lane 1, non-
treated cells; lane 2, bacillus Calmette-Guerin (BCG) 1 x 105 colony-
forming units (CFU)/ml; lanes 3 and 4, rhIFN--y 50 and 500 U/ml,
respectively; lane 5, BCG 1 x 105 CFU/ml and rhIFN-y 50 U/ml; lane 6,
BCG 1 x 105 CFU/ml and rhIFN-y 500 U/ml; lane 7, lipopolysacchar-
ide (LPS) 20 ,g/ml.
detectable levels of TNF-a mRNA without stimulation.
TNF-a mRNA was not clearly detected after 4 h of stimulation
with BCG or rhIFN-y 50 U/ml alone. The maximum signal
came out when the cells were stimulated by BCG combined
with IFN--y 50 U or 500 U (Fig. 1). PBMC also showed barely
detectable levels ofTNF-a mRNA without stimulation, but the
expression of TNF-a mRNA greatly increased with the stimu-
lation of BCG. TNF-a mRNA production ofPBMC was more
enhanced by the addition of IFN--y to BCG stimulation;
however, there was no significant difference between the addi-
tion of IFN-'y 50 U/ml and of 500 U/ml to BCG (Fig. 2). The in
vivo effect ofBCG on the production ofTNF-a in bladders and
spleens shown below was then observed.
TNF-a mRNA induction in spleens and bladders ofmice
The bladders of mice were electrocoagulated, and intravesically
implanted with MBT-2 cells, and were weekly instilled with
BCG for 5 weeks. The mice were killed 7 days after each BCG
instillation, and spleens and bladders were dissected out to
observe TNF-a mRNA expression. The maximum signal of
TNF-a mRNA of spleens was observed at the first or second
intravesical BCG instillation, and a higher level of TNF-a
mRNA was sustained during BCG treatment, but the signal
slightly decreased with time (Figs 3 and 4). Maximum produc-
tion of TNF-a mRNA in bladder tissues was observed after the
first and fifth intravesical BCG treatments. The signals of
TNF-a mRNA of bladders were highly sustained during BCG
treatment. The L(S) cell, a TNF-a-sensitive L cell line which
produces little TNF-a mRNA, and the L(R) cell, a TNF-a-
resistant L cell line which produces high amounts of TNF-a
mRNA, were used as controls [28] (data not shown).
The productions of TNF-a mRNA in the spleens and
bladder tissues were studied to observe the effect of IFN--y in
addition to BCG treatment. rmIFN--y (3000 U/mouse) was
instilled into mice bladders 3 days after BCG instillation, in
the expectation that IFN--y maintains the activated state of
monocyte/macrophage cell lineage of bladder tissue by BCG
treatment. However, there was no significant change ofTNF-a
mRNA production in spleens and bladders compared with the
BCG-alone treatment group (Figs 4 and 5).
yactin
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Fig. 2. Northern blot analysis of TNF-a mRNA of peripheral blood
mononuclear cells (PBMC) of two normal persons. Each lane was
loaded with 2 ttg/well of total cellular RNA. Lane 1, non-treated cells;
lane 2, bacillus Calmette-Guerin (BCG) 20 og/ml; lanes 3 and 4,
rhIFN-y 50 and 500 U/ml, respectively; lane 5, BCG 20,g/ml and
rhIFN--y 50 U/ml; lane 6, BCG 20 tzg/ml and rhIFN--y 500 U/ml; lane 7,
lipopolysaccharide (LPS) 20 ig/ml.
DISCUSSION
This study shows that C3H/He mice instilled with intravesical
BCG produce TNF-a mRNA in the spleen. TNF-a mRNA
was highly induced by the first or second intravesical BCG
instillation in the spleen. This result suggests that the systemic
immune response may be influenced by local treatment of
BCG. In our previous study, peritoneal macrophages of
guinea pigs treated weekly with intravesical BCG for 6 weeks
produced high amounts of TNF-a, especially at the second or
third week [15]. The serum TNF-a level was also slightly
increased after BCG immunotherapy in superficial bladder
cancer patients [15]. According to these data, it is considered
that intravesical BCG treatment systemically influences the
immune system. The positive conversion of purified protein
derivative (PPD) skin tests in patients treated with intravesical
BCG correlates with the tumour-free status [29-31]; therefore,
the TNF-a produced in the spleen may play an important role
in the mechanisms of BCG immunotherapy in superficial
bladder cancer.
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Fig. 3. Slot blot analysis ofTNF-a mRNA of spleens ofmice treated with bacillus Calmette-Gu6rin (BCG) only. MBT-2 cells (5 x 105)
were implanted into the bladders ofmice after electrocauterization, and BCG (1 x 105 colony-forming units (CFU)) was intravesically
injected weekly. Spleens were removed to observe the expression ofTNF-a mRNA after 1 week of final BCG instillation. Each slot was
loaded with 20 pg of total cellular RNA. (a) Slot blot analysis ofTNF-a mRNA of spleens ofmice+. Numbers indicate the number of
BCG treatments and the number of mice, respectively. (b) Band intensity of each slot is expressed on absorbance by laser scanning
densitometry.
several urological malignancies [32], but the studies of intrave-
sical IFN--y therapy for superficial transitional cell carcinoma
are primitive, and most studies have been performed with
IFN-ca [33-34]. In this study, the applicability of IFN--y
combined with BCG immunotherapy was evaluated by obser-
ving the change of TNF-a mRNA level. In vitro, IFN-'y
augments TNF-a mRNA production by BCG in HL-60 and
PBMC, compared with that of IFN--y or BCG stimulation
alone. This synergy may be due to the activation of macro-
phages and the increased number of TNF receptors by IFN-7
(a)
[35]. Since many toxicities are manifested by in vivo treatment of
TNF-a [36], although combined stimulation of TNF-a and
IFN--y has demonstrated synergistic cytotoxic activity [37-40],
we treated the mice with BCG followed by IFN--y after 3 days
to maintain continuously the activated state of macrophages
and other immune cells. Unexpectedly, however, there was no
significant increase of TNF-a mRNA production in mice
spleens and bladders. This result may be due to poor absorp-
tion of IFN--y into the bladder tissue, or loss of the priming
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Fig. 4. Slot blot analysis ofTNF-a mRNA of spleens of mice treated with bacillus Calmette-Guerin (BCG) and/or IFN--y. Mice were
treated with the same method as in Fig. 3, while IFN--y (3000 U) was intravesically instilled on day 3 after each BCG instillation. Each
slot was loaded with 20 pg of the total cellular RNA. (a) Slot blot analysis ofTNF-a mRNA of spleens ofmice treated with BCG and/
or IFN--y +. Numbers indicate the number ofBCG and/or IFN-y treatments and the number of mice, respectively. (b) Band intensity
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Fig. 5. Slot blot analysis ofTNF-a mRNA of bladders of mice treated with bacillus Calmette-Guerin (BCG) and/or IFN--y. Refer to
the legend of Fig. 4 for the treatment of mice. Each slot was loaded with 5 tig of the total cellular RNA. (a) Slot blot analysis ofTNF-a
mRNA of bladders of mice treated with BCG and/or IFN- + . Numbers indicate the numbers of BCG and/or IFN-y treatments and
the number of mice, respectively. (b) Band intensity of each slot is expressed on absorbance by laser scanning densitometry.
Hybridization was performed on the same filter.
The high expression of TNF-a mRNA of bladder tissue by
intravesical BCG treatment shows that TNF-a produced in
bladder tissue may play an important role in direct killing of
nearby tumour cells. A preliminary attempt at intravesical
therapy of superficial bladder cancer with TNF-a was made,
and the therapeutic effect was observed [41,42]. The concentra-
tion of TNF-a in the urine was increased from 4 to 8 h after
intravesical BCG treatment [13]. Our results show that TNF-a
in the urine may be the direct effect ofBCG on the bladder wall
as well as on the spleen. Histologically, small suburothelial
granulomas consist of mononuclear cells, and many mono-
nuclear cells can be found in the suburothelium after intrave-
sical BCG treatment [43,44], and the number of leucocytes,
monocytes/macrophages and T lymphocytes are significantly
increased in the urine of patients with superficial bladder cancer
after intravesical immunotherapy with BCG [45]. BCG can also
be found in the phagosome of phagocytic cells in the bladder
wall after intravesical BCG treatment; therefore, macrophages
and immigrated monocytes in bladder tissue produce TNF-a
by BCG treatment. Along with our previous report, which
showed that production of TNF-a by alveolar macrophages
from patients with pulmonary tuberculosis is increased more
than that of normal persons [46], this present study shows that
TNF-a from local tissue may be associated with anti-tumour
activity. As a result, this study demonstrated that TNF-a
production after intravesical administration of BCG may
possibly come not only from systemic production by BCG-
primed splenocytes, but also from local production by mono-
nuclear cells infiltrated on the bladder wall.
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